
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. is poised for growth, supported by a projected 12.5% increase in operating expenses alongside the anticipation of achieving positive EBITDA by 2026. The company is experiencing momentum in its market presence, highlighted by a 42% two-year revenue growth in the U.S. and an increase in procedures per physician, indicating a strengthened demand for its minimally invasive surgical implant systems. With a robust net cash balance of $110 million as of 3Q25, SI-BONE is well-positioned to capitalize on growth opportunities in the underpenetrated SI joint fusion market, particularly with the adoption of its innovative product offerings like iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite.
Bears say
The financial analysis of SI-BONE Inc. indicates several factors contributing to a negative outlook. The company is experiencing a projected decline in gross margin to 78% due to pricing pressures stemming from a shift in procedure mix towards lower-average selling price (ASP) deformity and trauma cases. Additionally, revenue growth is anticipated to be low-teens domestically, coupled with continued weakness in international markets, which raises concerns about overall profitability amid competitive threats and potential patent expirations.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares